Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions.

Autor:	Albu MT; Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany., Matei AE; Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany., Distler JHW; Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany., Giesel FL; Department of Nuclear Medicine, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany.; Institute for Radiation Sciences, Osaka University, Osaka, Japan., Mori Y; Department of Nuclear Medicine, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University; Düsseldorf, Germany.
Jazyk:	angličtina
Zdroj:	Rheumatology and immunology research [Rheumatol Immunol Res] 2024 Oct 21; Vol. 5 (3), pp. 152-156. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).
DOI:	10.2478/rir-2024-0021
Abstrakt:	Interstitial lung diseases (ILD) encompass a wide range of disorders characterized by alveolar inflammation and fibrotic tissue remodeling, marked by significant morbidity and mortality. Systemic sclerosis (SSc), among other connective tissue diseases, is a frequent cause of ILD. Assessment of pulmonary fibrosis is frequently constrained by the delayed manifestations of profibrotic activation of fibroblasts, which results in late macroscopic alterations detectable by standard imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) scans. 68Ga-labeled fibroblast activation protein inhibitors (68Ga-FAPI [fibroblast activation protein inhibitor]) are novel radionuclides used in the selective positron emission tomography/computed tomography (PET/CT) detection of profibrotic fibroblasts, a key player in fibrotic tissue remodeling. Application of 68Ga-FAPI in different target organs undergoing fibrosis, such as lung and heart, highlights its efficacy in detecting ongoing fibrotic processes, since FAPI tracer uptake has been correlated with clinical disease progression markers in SSc-ILD. This feature could enable physicians to detect subclinical fibrotic activity and tailor an individualised therapy plan on a case by case basis. The use of 68Ga-FAPI in ILD and other fibrotic conditions may emerge as a novel tool in future clinical practice for both activity monitoring and treatment optimisation. Other tracers tested in ILD of different etiologies have shown promising results and may in future also be considered for potential application in SSc-ILD. (© 2024 Mihai Tudor Albu, Alexandru-Emil Matei, Jörg H. W. Distler, Frederik L. Giesel, Yuriko Mori, published by De Gruyter on behalf of NCRC-DID.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu